Program Director's Choice from SABCS2025 - Part 1 : Giredestrant Improves Disease-free Survival in Patients With Early-stage Breast Cancer in Phase III lidERA Trial

Kate Lathrop, MD discuss one of the high impact, clinically relevant, clinical trial, the lidERA trial that were presented at the San Antonio Breast Cancer Symposium 2025.

Program Director's Choice from SABCS2025 - Part 2: Sacituzumab Govitecan for Endocrine Therapy-refractory Advanced Breast Cancers

Kate Lathrop, MD discuss one of the high impact, clinically relevant, clinical trial, the ASCENT-07 trial that were presented at the San Antonio Breast Cancer Symposium 2025.

Program Director's Choice from SABCS2025 - Part 3: Adding Tucatinib to First-line Maintenance Therapy Delayed Disease Progression in HER2-positive Metastatic Breast Cancer in HER2CLIMB-05 Trial

Kate Lathrop, MD discuss one of the high impact, clinically relevant, clinical trial, the HER2CLIMB-05 trail that were presented at the San Antonio Breast Cancer Symposium 2025.

Highligths of SABCS 2025

Prof. Virginia G. Kaklamani discuss some of the high impact, clinically relevant, clinical trials that were presented at the San Antonio Breast Cancer Symposium 2025, like the lidERA, HER2CLIMB-05 and WISDOM trial.